| Literature DB >> 35965789 |
Yangyun Wang1, Chaoliang Shi1, Jiawei Wang1, Guowei Shi1.
Abstract
Background: The symptoms of overactive bladder (OAB) are highly bothersome to patients. In behavioral therapy, traditional pelvic floor muscle training (PFMT) can be boring and monotonous, which can cause poor compliance. It's important to establish a new safe and effective crotch-pelvic floor functional reconstruction training method [Yun-type pelvic floor optimal training (Yun-type training)] for OAB patients.Entities:
Keywords: Yun-type pelvic floor optimal training therapy; mild to moderate overactive bladder; pelvic floor muscle training (PFMT)
Year: 2022 PMID: 35965789 PMCID: PMC9372683 DOI: 10.21037/atm-22-3357
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Flow chart of research scheme. OAB, overactive bladder; PFMT, pelvic floor muscle training.
Include the baseline characteristics of the patient
| Variable | Control (n=67) | Intervention (n=83) | P value |
|---|---|---|---|
| Age (years) | 37.00 (33.00, 42.00) | 37.00 (32.00, 42.00) | 0.914 |
| BMI (kg/m2) | 38.00 (34.00, 42.00) | 30.20 (29.10, 31.90) | <0.001 |
| OABSS | 6.00 (4.00, 8.00) | 5.00 (4.00, 7.00) | 0.627 |
| Urine in daytime | 0.882 | ||
| 0 | 24 (35.82) | 27 (32.53) | |
| 1 | 32 (47.76) | 43 (51.81) | |
| 2 | 11 (16.42) | 13 (15.66) | |
| Nocturia | 0.615 | ||
| 0 | 9 (13.43) | 13 (15.66) | |
| 1 | 29 (43.28) | 38 (45.78) | |
| 2 | 23 (34.33) | 21 (25.30) | |
| 3 | 6 (8.96) | 11 (13.25) | |
| Urgency | 0.420 | ||
| 2 | 31 (46.27) | 49 (59.04) | |
| 3 | 23 (34.33) | 21 (25.30) | |
| 4 | 12 (17.91) | 11 (13.25) | |
| 5 | 1 (1.49) | 2 (2.41) | |
| UUI | 0.411 | ||
| 0 | 20 (29.85) | 19 (22.89) | |
| 1 | 22 (32.84) | 37 (44.58) | |
| 2 | 18 (26.87) | 22 (26.51) | |
| 3 | 7 (10.45) | 5 (6.02) | |
| PPBC | 0.048 | ||
| 2 | 0 (0.00) | 8 (9.64) | |
| 3 | 12 (17.91) | 15 (18.07) | |
| 4 | 30 (44.78) | 27 (32.53) | |
| 5 | 25 (37.31) | 33 (39.76) | |
| IIQ-7 | 50.00 (45.00, 60.00) | 55.00 (45.00, 60.00) | 0.834 |
| UDI-6 | 40.00 (35.00, 50.00) | 35.00 (30.00, 50.00) | 0.124 |
| Qave | 10.00 (9.00, 10.00) | 10.00 (8.00, 12.00) | 0.913 |
| Qmax | 20.00 (17.00, 21.00) | 21.00 (18.00, 23.00) | 0.054 |
| VV | 215.00 (200.00, 225.00) | 210.00 (180.00, 250.00) | 0.646 |
| PVR | 14.00 (8.00, 20.00) | 12.00 (8.00, 20.00) | 0.698 |
| CRP | 2.10 (1.80, 3.60) | 3.00 (1.40, 4.10) | 0.875 |
| FSFI | 23.00 (21.40, 24.20) | 22.00 (20.20, 23.40) | 0.061 |
| Sexual desire | 3.60 (3.60, 4.20) | 4.00 (2.80, 4.00) | 0.106 |
| Arousal | 4.20 (3.60, 4.20) | 3.80 (3.20, 4.40) | 0.332 |
| Damp | 3.60 (3.00, 4.20) | 3.00 (2.40, 4.00) | <0.001 |
| Pain | 4.00 (3.60, 4.40) | 4.00 (3.60, 4.40) | 0.798 |
| Climax | 3.60 (2.80, 3.60) | 3.20 (2.80, 3.60) | 0.881 |
| Satisfaction | 3.80 (3.60, 4.40) | 4.20 (3.40, 4.20) | 0.490 |
| Type I muscle strength | 20.80 (19.10, 22.40) | 20.90 (18.20, 24.30) | 0.654 |
| Type II muscle strength | 25.30 (24.10, 26.50) | 25.50 (23.20, 28.10) | 0.391 |
| Pelvic floor muscle tone | 9.70 (8.00, 10.60) | 8.90 (7.10, 11.40) | 0.578 |
| Sex partner satisfaction | 4.00 (3.00, 6.00) | 3.00 (3.00, 4.00) | 0.012 |
Data are shown as n (%) or median (interquartile range). OABSS, overactive bladder symptoms; UUI, urge urinary incontinence; VV, voiding volume; UDI-6, urogenital distress inventory-6; PPBC, patient’s perception of bladder condition; IIQ-7, incontinence impact questionnaire-7; Qave, average flow rate; CRP, C-reactive protein; Qmax, maximum flow rate; PVR, postvoid residual urine volume; FSFI, female sexual function index.
Comparison of the treatment effects between the intervention and control groups
| Variables | Groups | Baseline | 6 weeks | 14 weeks | P value | ||
|---|---|---|---|---|---|---|---|
| Time | Group | Time × group | |||||
| OABSS | Control | 6.12 (2.64) | 4.49 (2.22) | 1.87 (1.38) | 0.815 | 0.469 | <0.001 |
| Intervention | 5.95 (2.52) | 2.13 (1.49) | 4.18 (1.62) | ||||
| P value | 0.693 | <0.001 | <0.001 | ||||
| Urine | Control | 0.81 (0.70) | 0.67 (0.56) | 0.18 (0.39) | 0.699 | 0.425 | <0.001 |
| Intervention | 0.83 (0.68) | 0.36 (0.48) | 0.77 (0.61) | ||||
| P value | 0.823 | <0.001 | <0.001 | ||||
| Nocturia | Control | 1.39 (0.83) | 1.36 (0.81) | 0.79 (0.59) | 0.984 | 0.177 | <0.001 |
| Intervention | 1.36 (0.90) | 0.61 (0.64) | 0.82 (0.57) | ||||
| P value | 0.853 | <0.001 | 0.766 | ||||
| Urgency | Control | 2.75 (0.80) | 1.70 (0.67) | 0.69 (0.58) | 0.641 | 0.248 | <0.001 |
| Intervention | 2.59 (0.81) | 0.86 (0.84) | 1.78 (0.72) | ||||
| P value | 0.242 | <0.001 | <0.001 | ||||
| UUI | Control | 1.18 (0.98) | 0.76 (0.76) | 0.21 (0.41) | 0.788 | 0.107 | <0.001 |
| Intervention | 1.16 (0.85) | 0.30 (0.49) | 0.81 (0.71) | ||||
| P value | 0.881 | <0.001 | <0.001 | ||||
| PPBC | Control | 4.19 (0.72) | 3.19 (0.74) | 1.79 (0.75) | 0.125 | 0.846 | <0.001 |
| Intervention | 4.02 (0.99) | 2.10 (0.55) | 3.08 (0.57) | ||||
| P value | 0.241 | <0.001 | <0.001 | ||||
| UDI-6 | Control | 41.19 (8.79) | 26.37 (10.35) | 14.45 (7.95) | 0.236 | 0.153 | <0.001 |
| Intervention | 39.17 (9.38) | 16.51 (7.99) | 20.51 (7.99) | ||||
| P value | 0.179 | <0.001 | <0.001 | ||||
| IIQ-7 | Control | 52.13 (9.41) | 37.13 (9.41) | 17.51 (8.75) | <0.001 | 0.936 | <0.001 |
| Intervention | 52.90 (10.90) | 17.90 (10.90) | 32.90 (10.90) | ||||
| P value | 0.649 | <0.001 | <0.001 | ||||
| VV | Control | 214.25 (23.36) | 223.51 (22.98) | 276.49 (33.97) | 0.644 | 0.663 | <0.001 |
| Intervention | 213.19 (41.65) | 275.90 (37.60) | 235.90 (37.60) | ||||
| P value | 0.853 | <0.001 | <0.001 | ||||
| Qave | Control | 9.82 (1.36) | 10.54 (1.76) | 11.24 (1.97) | 0.525 | 0.284 | 0.056 |
| Intervention | 10.13 (2.18) | 10.43 (2.51) | 10.17 (2.32) | ||||
| P value | 0.309 | 0.776 | 0.003 | ||||
| Qmax | Control | 19.78 (2.88) | 21.43 (3.88) | 21.60 (3.16) | 0.203 | <0.001 | <0.001 |
| Intervention | 20.36 (3.63) | 26.57 (2.87) | 25.57 (2.82) | ||||
| P value | 0.284 | <0.001 | <0.001 | ||||
| PVR | Control | 14.43 (8.71) | 14.81 (7.50) | 14.79 (7.62) | 0.54 | 0.297 | 0.397 |
| Intervention | 14.00 (8.19) | 13.78 (6.38) | 15.46 (6.32) | ||||
| P value | 0.755 | 0.368 | 0.559 | ||||
| CRP | Control | 2.77 (1.53) | 2.68 (1.45) | 2.72 (1.34) | 0.544 | 0.67 | 0.404 |
| Intervention | 2.79 (1.52) | 2.80 (1.51) | 2.82 (2.28) | ||||
| P value | 0.938 | 0.624 | 0.749 | ||||
| FSFI | Control | 22.56 (1.85) | 25.27 (1.85) | 29.38 (1.49) | <0.001 | 0.007 | <0.001 |
| Intervention | 21.88 (2.33) | 28.24 (2.34) | 24.89 (2.27) | ||||
| P value | 0.053 | <0.001 | <0.001 | ||||
| Sexual desire | Control | 3.75 (0.44) | 4.37 (0.79) | 5.43 (0.45) | 0.042 | <0.001 | <0.001 |
| Intervention | 3.56 (0.80) | 5.36 (0.72) | 3.20 (0.82) | ||||
| P value | 0.087 | <0.001 | <0.001 | ||||
| Arousal | Control | 3.87 (0.62) | 4.54 (0.62) | 5.57 (0.67) | <0.001 | 0.179 | <0.001 |
| Intervention | 3.81 (0.98) | 5.27 (0.87) | 4.86 (0.87) | ||||
| P value | 0.625 | <0.001 | <0.001 | ||||
| Damp | Control | 3.70 (0.62) | 4.01 (0.71) | 3.97 (0.68) | 0.246 | 0.017 | 0.164 |
| Intervention | 3.28 (0.75) | 3.87 (0.70) | 3.77 (0.66) | ||||
| P value | <0.001 | 0.205 | 0.071 | ||||
| Climax | Control | 3.35 (0.58) | 3.69 (0.53) | 4.23 (0.60) | 0.557 | 0.107 | <0.001 |
| Intervention | 3.24 (0.56) | 4.22 (0.65) | 4.13 (0.58) | ||||
| P value | 0.258 | <0.001 | 0.299 | ||||
| Pain | Control | 3.97 (0.57) | 4.16 (0.53) | 4.72 (0.63) | 0.327 | 0.14 | <0.001 |
| Intervention | 4.02 (0.45) | 4.35 (0.42) | 4.26 (0.46) | ||||
| P value | 0.559 | 0.017 | <0.001 | ||||
| Satisfaction | Control | 3.92 (0.65) | 4.49 (0.50) | 5.46 (0.31) | 0.244 | 0.798 | <0.001 |
| Intervention | 3.98 (0.53) | 5.16 (0.39) | 4.67 (0.38) | ||||
| P value | 0.557 | <0.001 | <0.001 | ||||
| Type I muscle strength | Control | 20.84 (1.93) | 23.07 (1.81) | 31.91 (1.85) | <0.001 | 0.047 | <0.001 |
| Intervention | 21.38 (3.40) | 29.30 (3.13) | 23.48 (3.40) | ||||
| P value | 0.248 | <0.001 | <0.001 | ||||
| Type II muscle strength | Control | 25.28 (1.80) | 28.94 (1.78) | 37.04 (1.76) | <0.001 | 0.834 | <0.001 |
| Intervention | 25.70 (3.41) | 34.57 (3.22) | 29.60 (3.41) | ||||
| P value | 0.367 | <0.001 | <0.001 | ||||
| Pelvic floor muscle tone | Control | 9.40 (2.14) | 6.68 (1.82) | 4.16 (1.56) | <0.001 | 0.751 | <0.001 |
| Intervention | 9.10 (2.38) | 4.75 (1.39) | 6.42 (2.10) | ||||
| P value | 0.418 | <0.001 | <0.001 | ||||
| Sex partner satisfaction | Control | 4.07 (1.68) | 5.72 (1.71) | 7.46 (1.02) | 0.086 | 0.011 | <0.001 |
| Intervention | 3.24 (0.92) | 7.10 (0.95) | 5.76 (1.63) | ||||
| P value | <0.001 | <0.001 | <0.001 | ||||
Data are shown as mean (SD). OABSS, overactive bladder symptoms; UUI, urge urinary incontinence; VV, voiding volume; PPBC, patient’s perception of bladder condition; IIQ-7, incontinence impact questionnaire-7; UDI-6, urogenital distress inventory-6; Qave, average flow rate; CRP, C-reactive protein; Qmax, maximum flow rate; PVR, postvoid residual urine volume; FSFI, female sexual function index.